Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFELMQ)

Drug Name

AMEP Drug Info

Synonyms

(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; AMeP; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 1	[1]

Cross-matching ID

PubChem CID: 14017
ChEBI ID: CHEBI:28812
CAS Number: CAS 1066-51-9
TTD Drug ID: DMFELMQ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-V/beta-3 (ITGAV/B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilengitide	DMEAOZ0	Rheumatoid arthritis	FA20	Phase 3	[3]
ATN-161	DM4T9RS	Renal cell carcinoma	2C90	Phase 2	[4]
Intetumumab	DMBXEG9	Prostate cancer	2C82.0	Phase 2	[5]
VLTS-589	DM4O17U	Peripheral vascular disease	BD4Z	Phase 2	[6]
Fluciclatide F-18	DME01HT	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
SF0166	DM4NK3J	Diabetic macular edema	9B71.02	Phase 1/2	[8]
Vitaxin	DMHCLVQ	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[9]
SB-267268	DMIBFAV	Osteoporosis	FB83.0	Discontinued in Phase 1	[10]
SB-273005	DMV7M1H	Osteoporosis	FB83.0	Discontinued in Phase 1	[11]
PS-388023	DM8P05S	Ocular disease	1F00.1Z	Terminated	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Integrin alpha-5/beta-1 (ITGA5/B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATN-161	DM4T9RS	Renal cell carcinoma	2C90	Phase 2	[4]
Volociximab	DMNQG24	Non-small-cell lung cancer	2C25.Y	Phase 2	[13]
F-200	DMVWZN1	Ocular disease	1F00.1Z	Terminated	[14]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-5/beta-1 (ITGA5/B1)	TTH4QIS	ITA5_HUMAN-ITB1_HUMAN	Modulator	[2]
Integrin alpha-V/beta-3 (ITGAV/B3)	TT69TQN	ITAV_HUMAN-ITB3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
2	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
3	The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449.
4	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
5	A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
6	AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.
7	Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000 Jan 15;95(2):368-74.
10	SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
11	Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthri... Arthritis Rheum. 2001 Jan;44(1):128-37.
12	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13	Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.
14	US patent application no. 8,541,413, Sustained release eye drop formulations.